COMMUNIQUÉS West-GlobeNewswire

Avadel Pharmaceuticals Announces FDA Agreement to Reduce the Sample Size for the Ongoing Pivotal Phase 3 Study for Once-Nightly FT218; Full Enrollment Now Expected by End of 2019
23/09/2019
FDA agrees with Company’s proposed changes to the statistical analysis plan for the REST-ON Phase 3 study for once-nightly sodium oxybate, FT218 Reduces estimated time to completion by up to 12 months; now expected to [...]
First Data On Combination Of Enlivex’s Allocetra-OTS Immunotherapy and CAR-T Therapy Designed For Treating Solid Tumors Revealed At The Joint IIS-ISCR Special 2019 Conference
23/09/2019
Nes-Ziona, Israel, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq:ENLV), a clinical-stage immunotherapy company, today announced the first presentation of its preclinical studies, which were [...]
TG Therapeutics Announces Data Presentations at the XVIII International Workshop on Chronic Lymphocytic Leukemia (iwCLL)
23/09/2019
Phase 2 study of umbralisib monotherapy in BTK/PI3K-delta intolerant CLL reports an estimated median progression-free survival (PFS) of 23.5 months (n=50) with 58% of patients on umbralisib longer than their prior [...]
ADMA Biologics to Present at 2019 Cantor Global Healthcare Conference
23/09/2019
RAMSEY, N.J. and BOCA RATON, Fla., Sept. 23, 2019 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical and specialty immunoglobulin [...]
BioCryst Appoints Helen Thackray, M.D., to Board of Directors
23/09/2019
RESEARCH TRIANGLE PARK, N.C., Sept. 23, 2019 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company has appointed clinical rare disease expert, Helen Thackray, M.D., FAAP, to [...]
Athenex Completes Construction of New API Facility in Chongqing
23/09/2019
BUFFALO, N.Y., Sept. 23, 2019 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of [...]
Athenex to Present at the 2019 San Antonio Breast Cancer Symposium
23/09/2019
BUFFALO, N.Y., Sept. 23, 2019 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of [...]
Athenex to Highlight Oral Paclitaxel Clinical Programs Targeting Various Solid Tumors at the ESMO Congress 2019
23/09/2019
BUFFALO, N.Y., Sept. 23, 2019 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of [...]
Akcea Announces CEO Transition and Elects Two New Board Members
23/09/2019
Damien McDevitt, Ph.D. appointed interim CEO; Michael Yang and Joseph ‘Skip’ Klein join Board of Directors BOSTON, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate [...]
Amydis Awarded NIH Ph2A Grant for Cerebral Amyloid Angiopathy
23/09/2019
SAN DIEGO, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Amydis, Inc., a privately-held pharmaceutical company developing proprietary drugs to detect, monitor, and screen for amyloid-related diseases, announced today that they [...]
Scilex Holding Announces Confidential Submission of Draft Registration Statement for Proposed Initial Public Offering
23/09/2019
SAN DIEGO, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Scilex Holding Company (Scilex), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE), announced that it has confidentially submitted a draft [...]
ReWalk Robotics to Present at the Sidoti & Company Conference on September 25th
23/09/2019
MARLBOROUGH, Mass. and YOKNEAM ILIT, Israel, Sept. 23, 2019 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (“ReWalk” or the “Company”) (Nasdaq: RWLK) today announced that Larry Jasinski, Chief Executive Officer, will present [...]
Cyclacel Pharmaceuticals to Present at the Ladenburg Thalmann 2019 Healthcare Conference
23/09/2019
BERKELEY HEIGHTS, N.J., Sept. 23, 2019 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on [...]
GW Pharmaceuticals receives European Commission approval for EPIDYOLEX® (cannabidiol) for the treatment of seizures in patients with two rare, severe forms of childhood-onset epilepsy
23/09/2019
Cannabidiol oral solution is the first plant-derived cannabis-based medicine to be approved by the European Medicines Agency (EMA) Cannabidiol oral solution contains highly purified, plant-derived cannabidiol (CBD), a [...]
Ovid Therapeutics Announces Positive Initial Data from Ongoing ENDYMION Open-Label Extension Trial of Soticlestat in People with Rare Epilepsies
23/09/2019
Sustained and Progressively-Improving Median Seizure Frequency Reduction Reaching 84-90% with Prolonged Treatment of Soticlestat in this Difficult-to-Treat Patient Population Soticlestat Continues to Advance in Rare [...]
GW Pharmaceuticals receives European Commission approval for EPIDYOLEX® (cannabidiol) for the treatment of seizures in patients with two rare, severe forms of childhood-onset epilepsy
23/09/2019
Cannabidiol oral solution is the first plant-derived cannabis-based medicine to be approved by the European Medicines Agency (EMA) Cannabidiol oral solution contains highly purified, plant-derived cannabidiol (CBD), a [...]
Cambrex Corporation Announces Expiration of “Go Shop” Period Under Merger Agreement
23/09/2019
EAST RUTHERFORD, N.J., Sept. 23, 2019 (GLOBE NEWSWIRE) -- Cambrex Corporation (NYSE: CBM) (the “Company” or “Cambrex”) today announced the expiration, as of 12:01 a.m., Eastern Time, on September 22, 2019, of the 45-day [...]
Precision BioSciences Appoints David Thomson, PhD, as Chief Operating Officer
23/09/2019
DURHAM, N.C., Sept. 23, 2019 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a genome editing company dedicated to improving life through the application of its pioneering, proprietary ARCUS ® platform, [...]
Plus Therapeutics to Receive $4.6MM Reimbursement Payment
23/09/2019
AUSTIN, Texas, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”) today announced that it received notice from the U.S. Department of Health and Human Services / Office of the [...]

Pages